Patterns of failure after adjuvant "sandwich" chemo-radio-chemotherapy in locally advanced (stage III-IVA) endometrial cancer.
Chemotherapy
Endometrial cancer
Locally advanced
Radiotherapy
Sandwich
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
04
07
2020
accepted:
23
07
2020
pubmed:
1
8
2020
medline:
25
2
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
To investigate oncological outcomes and patterns of recurrence of patients undergoing adjuvant "sandwich" chemo-radio-chemotherapy for locally advanced endometrial cancer. This is a multi-institutional retrospective study evaluating chart of consecutive patients undergoing chemo-radio-chemotherapy for FIGO stage III-IVA endometrial caner. The study population included 45 patients who had adjuvant sandwich regimen. Median age of the study population was 66 years. The majority of patients were diagnosed with endometrioid histology and with stage III disease. After a median follow-up of 35 months, 15 patients developed recurrent disease. Three-year disease-free and overall survivals was 45% and 81%, respectively. Three-years site-specific disease-free survival was 85%, 92% and 48% for local, loco-regional, and distant recurrence, respectively. All patients included in the study had nodal dissection. Nodal assessment included: sentinel node mapping, sentinel node mapping plus backup lymphadenectomy and lymphadenectomy in 15, 6 and 24 patients, respectively. The latter group included four patients detected by suspected enlarged nodes, intraoperatively. Even after the exclusion of patients with enlarged nodes, the type of nodal assessment did not impact on survival outcomes (p > 0.2). Positive peritoneal cytology was the only factor associated with an increased risk of developing (any site) recurrence and distant-specific recurrence, independently. No factor predicted for overall survival. Adjuvant "sandwich" chemo-radio-chemotherapy for locally advanced endometrial cancer guarantee promising local and loco-regional controls, but distant failure rate is high, thus suggesting the need for applying other systemic treatment strategies for these patients.
Identifiants
pubmed: 32734325
doi: 10.1007/s00432-020-03339-y
pii: 10.1007/s00432-020-03339-y
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-820Références
Bogani G, Casarin J, Maggiore ULR, Ditto A, Pinelli C, Dellacqua A et al (2020) Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadenectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis. Gynecol Oncol 158:77–83
doi: 10.1016/j.ygyno.2020.04.691
Bogani G, Cromi A, Serati M, Di Naro E, Donadello N, Casarin J et al (2015) Chemotherapy reduces para-aortic node recurrences in endometrial cancer with positive pelvic and unknown para-aortic nodes. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 25:263–268
doi: 10.1097/IGC.0000000000000337
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martin A, Ledermann J et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 27:16–41
doi: 10.1093/annonc/mdv484
De Boer SM, Nout RA, Bosse T, Creutzberg CL (2019a) Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Rev Anticancer Ther 19:51–60
doi: 10.1080/14737140.2019.1531708
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309
doi: 10.1016/S1470-2045(18)30079-2
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al (2019b) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273–1285
doi: 10.1016/S1470-2045(19)30395-X
Geller MA, Ivy JJ, Ghebre R, Downs LSJ, Judson PL, Carson LF et al (2011) A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 121:112–117
doi: 10.1016/j.ygyno.2010.12.338
Goodman CR, Hatoum S, Seagle B-LL, Donnelly ED, Barber EL, Shahabi S et al (2019) Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer. Gynecol Oncol 153:41–48
doi: 10.1016/j.ygyno.2019.01.007
Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103:155–159
doi: 10.1016/j.ygyno.2006.02.007
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B et al (2014) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 46:2422–2431
doi: 10.1016/j.ejca.2010.06.002
Kauffman M (2020) A randomized, double-blind, phase 3 trial of maintenance with selinexor/ placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer. Available at www.cliniacltrials.gov . Last Accessed 08 Jun 2020
Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271
doi: 10.1038/sj.bjc.6603279
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA et al (2019) Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380:2317–2326
doi: 10.1056/NEJMoa1813181
Narasimhulu DM, Cope A, Riaz IB et al (2020) External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 30(797):805. https://doi.org/10.1136/ijgc-2020-001199
doi: 10.1136/ijgc-2020-001199
Onal C, Sari SY, Yildirim BA, Yavas G, Gultekin M, Guler OC et al (2019) A multi-institutional analysis of sequential versus “sandwich” adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma. J Gynecol Oncol 30:e28
doi: 10.3802/jgo.2019.30.e28
Onstad M, Ducie J, Fellman BM et al (2020) Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer 30(485):490. https://doi.org/10.1136/ijgc-2019-000807
doi: 10.1136/ijgc-2019-000807
Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol 24:36–44
doi: 10.1200/JCO.2004.00.7617
Schlappe BA, Weaver AL, McGree ME et al (2020) Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol 156(62):69. https://doi.org/10.1016/j.ygyno
doi: 10.1016/j.ygyno
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70:7–30
doi: 10.3322/caac.21590